Peptide · Recovery & Tissue Repair
BPC-157
A body-protection pentadecapeptide studied for how it may support the slow-healing places — a strained tendon, an irritable gut lining, a joint that lingers.
Available by consultation
What it is
Tissue Repair
BPC-157 (Body Protection Compound) is a synthetic 15-amino-acid peptide patterned on a protective sequence first identified in gastric juice. Unlike the growth-hormone peptides on this menu, it does not act on the endocrine axis at all — the research interest sits in localized repair: connective tissue, the gastrointestinal lining, and the local signaling that helps a damaged area rebuild. It is a compounded therapy, prescribed only when a licensed provider determines it is clinically appropriate for you.
BPC-157 is thought to work not by releasing a hormone, but by amplifying the body's own repair signaling in tissue that heals slowly. The pathways under study are what set it apart from every GH-based peptide on this page.
Angiogenic signaling
Early research points to BPC-157 interacting with the VEGFR2 and nitric-oxide pathways — the machinery behind forming new microvessels. Restoring local blood supply is what feeds a healing tendon, ligament, or wound bed the oxygen and nutrients it needs.
Growth-factor & fibroblast activity
It is studied for its influence on growth-factor receptor expression and on fibroblasts — the cells that lay down the collagen scaffolding connective tissue relies on to knit back together after strain or micro-injury.
Gut-lining & gut-brain protection
Because it traces to a gastroprotective sequence, much of the scientific attention lives in the GI tract — the mucosal lining and the gut-brain signaling axis — a focus that has no parallel among the muscle-and-metabolism GH peptides.
Candidacy
A considered fit, not a funnel.
BPC-157 tends to draw active adults working through a nagging soft-tissue issue, and people focused on gut resilience — a different profile than someone chasing sleep, lean mass, or fat loss from a growth-hormone peptide. It is used to support recovery, not as a substitute for surgical, orthopedic, or gastroenterology care. A provider reviews your history to decide whether it fits your goals.
- Adults recovering from a tendon, ligament, or joint strain
- Those focused on gut-lining resilience and GI comfort
- Active people seeking non-hormonal recovery support
- Anyone with an active or recent cancer diagnosis (angiogenic signaling is a theoretical concern)
- People who are pregnant or breastfeeding
- Anyone with a known hypersensitivity to the peptide or diluent
Expected Timeline
What to expect
BPC-157 is typically run as a focused repair course rather than an open-ended regimen — dosing is often concentrated during an active healing window, then wound down as the target area settles.
- 01
Weeks 1-2
Initiation
Your provider establishes a daily protocol — often subcutaneous, sometimes dosed near the area of concern, or oral for gut-focused goals — and confirms tolerability before continuing.
- 02
Weeks 3-6
Active repair
The core window where connective-tissue or gut-support goals are pursued. Many protocols hold a steady daily cadence here while you and your provider track how the target area responds.
- 03
Weeks 6-8+
Taper & reassess
Rather than continuing indefinitely, courses are commonly wound down and reassessed. Your provider decides whether a maintenance approach, a pause, or a stop makes sense.
Response varies from person to person, and BPC-157 is a compounded, provider-directed therapy. Your protocol, route, and duration are set and adjusted by your prescriber — the cadence above is illustrative, not a promise of any particular result.
The Science
Why clinicians reach for it.
The evidence base for BPC-157 is largely preclinical and early-stage. We describe the direction of research honestly — no invented trials, no promised outcomes.
Rooted in a protective protein
BPC-157 corresponds to a partial sequence of a protein found in gastric juice — the reason so much research attention has historically centered on gastrointestinal protection and mucosal integrity.
Connective-tissue interest
There is genuine scientific curiosity around its role in tendon, ligament, and muscle healing, studied largely in animal and cell models rather than large human trials — part of why it remains a compounded, provider-gated option.
Not FDA-approved
BPC-157 is not an FDA-approved drug and is available only through compounding when a licensed provider deems it appropriate. It should be viewed as an emerging, supportive therapy — not an established treatment for any condition.
Our Standard of Care
Real transformation, with a friendly team that stands by you every step.
- 01.Provider-Supervised
- Licensed providers review your health profile and guide every treatment decision. You only move forward when a plan is right for you.
- 02.Personalized Plans
- GLP-1 and peptide protocols are titrated to your biology and your goals. No one-size-fits-all, no guesswork.
- 03.We Stand By You
- From eligibility review to ongoing check-ins, our care team supports you throughout your transformation — discreet shipping and secure messaging included.
Clinical Safety
No therapy is right for everyone.
What to know
Reported effects are generally mild and may include irritation, redness, or discomfort at the injection site, and occasional lightheadedness or nausea. Because human safety data is limited, any new or persistent symptom should be reported to your provider promptly.
Contraindications
Not appropriate during pregnancy or breastfeeding, or for anyone with a known hypersensitivity to the peptide or diluent. Given its angiogenic and growth-factor signaling, it is generally avoided in anyone with an active or recent malignancy. Share your full medical history — including any cancer history — so your provider can assess suitability.
MagsRX protocols are prepared by partner compounding pharmacies in the United States. Compounding pharmacies are regulated by both state boards and the FDA and have been part of American medicine since long before mass-manufactured drugs existed. The active ingredient is prepared per your protocol — supervised by your provider — and delivered direct to your door.
Frequently Asked
Questions worth asking before you begin.
No. It does not act on the GHRH axis or trigger growth-hormone release at all. Its studied pathways are angiogenesis, growth-factor signaling, and gut protection — localized repair rather than any systemic hormone effect, which is what makes it distinct from the GH peptides on our menu.
Sometimes. For gut-focused goals providers may use an oral form, while connective-tissue goals are more often approached subcutaneously — occasionally near the area of concern. Your prescriber recommends the route that matches what you're targeting.
BPC-157 is usually run as a defined repair course of several weeks and then reassessed, rather than taken indefinitely. Your provider sets and adjusts the duration based on how you respond and what you're working toward.
Explore More
Other therapies to consider.
Recovery StackBPC-157 / TB500
A two-peptide recovery stack that pairs BPC-157's localized repair focus with TB-500's systemic reach — so support isn't confined to one strained spot but extends across the soft tissue that moves with it.
Learn more →- Tissue Repair
BPC-157 Acetate
The same BPC-157 pentadecapeptide, prepared as the acetate salt — the biocompatible counter-ion chosen for a clean compounded preparation that avoids residual TFA.
Learn more → - Complete Repair Stack
BPC-157 / GHK-Cu / KPV / TB500
Our broadest repair stack — four peptides that pair BPC-157/TB-500 tissue and soft-tissue support with GHK-Cu copper-led skin remodeling and KPV's anti-inflammatory lane.
Learn more →
Begin
BPC-157 begins with a short assessment.
A licensed provider reviews every order and prescribes only if it is clinically appropriate for you. Your therapy is prepared by a partner compounding pharmacy and delivered discreetly to your door.